Don't miss M. Adamo discussing about the importance of lifetime management, minimising complications, ensuring valve durability and preserving coronary access for future interventions. Navitor™’ is presented, reviewing the VANTAGE trial with 0% moderate/severe PVL at 30 days, 97% technical success and very low mortality and stroke at one year, confirming Navitor’s safety and effectiveness in this population.